首页> 外文OA文献 >High dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: results of a pilot study.
【2h】

High dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: results of a pilot study.

机译:高剂量强度联合化疗治疗晚期上皮性卵巢癌:一项初步研究的结果。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Retrospective studies have recently demonstrated a significant correlation between dose intensity of chemotherapy and response rates and survival in various diseases including epithelial ovarian carcinoma. As part of a proposed randomised trial to assess the effect of dose intensity on outcome in ovarian carcinoma, a pilot study has been undertaken to determine the toxicity and efficacy of the high intensity therapy. Nineteen patients with advanced ovarian carcinoma received initial treatment with cisplatin 120 mg m-2 i.v. day 1, and cyclophosphamide 1,000 mg-2 i.v. day 1, given at 21-day intervals for six cycles. The average relative dose intensity of this therapy is 1.14 when compared with the CHAP regimen. Severe toxicity was experienced by most patients. The median received average relative dose intensity was 0.90, with only one patient receiving treatment to the proposed intensity. Randomised studies of the effect of dose intensity in ovarian carcinoma are essential, but an initial step must be to assess whether the proposed high dose treatment can be delivered.
机译:最近的回顾性研究表明,在包括上皮性卵巢癌在内的各种疾病中,化学疗法的剂量强度与缓解率和生存率之间存在显着相关性。作为评估剂量强度对卵巢癌结局影响的随机试验的一部分,已进行了一项初步研究,以确定高强度疗法的毒性和疗效。 19名晚期卵巢癌患者接受顺铂120 mg m-2 i.v的初始治疗。第1天和环磷酰胺1,000 mg-2 i.v.第1天,间隔21天,共六个周期。与CHAP方案相比,该疗法的平均相对剂量强度为1.14。大多数患者经历了严重的毒性反应。中位接受平均相对剂量强度为0.90,只有一名患者接受了建议强度的治疗。剂量强度对卵巢癌影响的随机研究至关重要,但是第一步必须是评估建议的高剂量治疗是否可以实施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号